Pricing Log in Create free account

Inhibrx Biosciences, Inc. (INBX) vs Nektar Therapeutics (NKTR)

Inhibrx Biosciences, Inc. and Nektar Therapeutics are both Biotechnology companies. Inhibrx Biosciences, Inc. and Nektar Therapeutics are of similar size ($1.3B and $1.3B). Inhibrx Biosciences, Inc. has the higher net margin (0.00% vs −287.8%) and the higher return on invested capital (0.00% vs −40.2%). Across the 14 metrics below, Inhibrx Biosciences, Inc. leads on 8 and Nektar Therapeutics on 6.

Valuation

Metric INBX NKTR Biotechnology median
P/E n/m n/m 8.50
P/S 446.70 21.67 9.71
P/B n/m 1.31 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 460.33 18.33 9.21
Earnings yield (9.89%) (18.73%) (33.15%)
Free cash flow yield (9.37%) (19.79%) (25.50%)

Profitability

Metric INBX NKTR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (257.80%) 0.00%
Net margin 0.00% (287.84%) 0.00%
Free cash flow margin 0.00% (428.72%) 0.00%
Return on equity (1,773.60%) (35.75%) (56.36%)
Return on assets (75.44%) (24.12%) (48.04%)
Return on invested capital 0.00% (40.20%) 0.00%

Growth

Metric INBX NKTR Biotechnology median
Revenue growth (TTM) — (27.15%) 6.02%
EPS growth (last fiscal year) (108.03%) (11.89%) 30.26%
Revenue growth, 5-year CAGR — (18.43%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric INBX NKTR Biotechnology median
Debt to equity (3.33) 0.00 0.00
Current ratio 5.07 10.42 4.72
Net debt to EBITDA 0.18 1.77 0.96

Dividend

Metric INBX NKTR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric INBX NKTR Biotechnology median
Market cap 1.33b 1.29b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack